[Which therapeutic prospects in the XXXX ?].

@entity1 @entity32 @entity295 @entity326 @entity5414 @entity1003 @entity134 @entity230 @entity204
OBJECTIVE: To evaluate recent data provided on new treatments of @entity1 with @entity326 . DATA EXTRACTION: A Medline search was performed to identify pertinent literature on the pathophysiology of @entity326 and treatment strategies from 1990 to 2003. Keywords were " @entity326 ", " @entity295 ", " @entity32 " and "management". DATA SYNTHESIS: Advances were performed in our current understanding of pathophysiology of @entity295 . The loss of homeostatic balance among the systemic inflammatory response and the disturbance of coagulation with generalized @entity1003 lead to organ failures and @entity204 . The administration of activated protein C (drotrecogin alfa) reducing this @entity1003 can decrease the mortality of @entity326 @entity1 . The modulation of @entity32 did not make it possible to improve survival of @entity326 @entity1 until now. The efficacy of low doses of @entity134 has been recently shown in @entity326 @entity1 . In addition, new data highlighted the interest of an early goal therapy in @entity1 with @entity295 who are admitted to emergency. CONCLUSION: The improvement of survival in @entity5414 @entity1 is a difficult challenge. The uses of different new therapeutic options like protein C reactive, @entity230 , or early goal therapy in association should make it possible to reduce the mortality in septic @entity1 .
